Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study

被引：0
|
作者：
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
De Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De la Mora
Zhou, Jianying
Perol, Maurice
Lee, Hyeong
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[3] Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Ist Europeo Oncol, Milan, Italy
[7] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Med Sur Hosp, Ctr Oncol, Mexico City, Mexico
[10] Peking Union Med Coll Hosp, Beijing, Peoples R China
[11] Chang Gung Mem Hosp, Taoyuan, Taiwan
[12] Inst Jalisciense Cancerol, Guadalajara, Mexico
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Ctr Leon Berard, Lyon, France
[15] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[16] Hosp Univ Virgen Macarena, Seville, Spain
[17] Okayama Univ Hosp, Okayama, Japan
[18] Mem Sloan Kettering Canc Ctr, New York, NY USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9000
引用
收藏
页数：1
相关论文
共 50 条
  • [31] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
    Zhang, Yongchang
    Zeng, Liang
    Zhang, Xiangyu
    Li, Yizhi
    Liu, Lingli
    Xu, Qinqin
    Yang, Haiyan
    Jiang, Wenjuan
    Lizaso, Analyn
    Qiu, Luting
    Hou, Ting
    Liu, Jun
    Peng, Ling
    Yang, Nong
    BMC MEDICINE, 2021, 19 (01)
  • [33] Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kobayashi, N.
    Aiko, H.
    Kamimaki, C.
    Mikami, N.
    Kubo, S.
    Tei, Y.
    Hirama, N.
    Katakura, S.
    Teranishi, S.
    Manabe, S.
    Yamamoto, M.
    Kudo, M.
    Kaneko, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [34] Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
    Heon, Stephanie
    Nishino, Mizuki
    Goldberg, Sarah B.
    Porter, Jennifer
    Sequist, Lecia V.
    Jackman, David Michael
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
    Yongchang Zhang
    Liang Zeng
    Xiangyu Zhang
    Yizhi Li
    Lingli Liu
    Qinqin Xu
    Haiyan Yang
    Wenjuan Jiang
    Analyn Lizaso
    Luting Qiu
    Ting Hou
    Jun Liu
    Ling Peng
    Nong Yang
    BMC Medicine, 19
  • [36] Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
    Reckamp, Karen L.
    Mack, Philip C.
    Ruel, Nora
    Frankel, Paul Henry
    Gitlitz, Barbara J.
    Li, Tianhong
    Koczywas, Marianna
    Gadgeel, Shirish M.
    Cristea, Mihaela C.
    Belani, Chandra Prakash
    Newman, Edward M.
    Gandara, David R.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
    Garassino, Marina C.
    Gadgeel, Shirish
    Speranza, Giovanna
    Felip, Enriqueta
    Esteban, Emilio
    Domine, Manuel
    Hochmair, Maximilian J.
    Powell, Steven F.
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Kurata, Takayasu
    Gray, Jhanelle E.
    Schwarzenberger, Paul
    Jensen, Erin
    Pietanza, M. Catherine
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 1992 - +
  • [38] A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naive EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
    Le, X.
    Patel, J.
    Shum, E.
    Sanborn, R. E.
    Baik, C. S.
    Shu, C. A.
    Kim, C.
    Fidler, M. D.
    Hall, R.
    Hanna, N.
    Mohindra, N.
    Sabari, J. K.
    Heeke, S.
    Hernandez, M.
    Gray, J. E.
    Heymach, J. V.
    Saltos, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1313 - S1314
  • [39] Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
    Gray, Jhanelle Elaine
    Owonikoko, Taofeek Kunle
    Kato, Terufumi
    Zorrilla, Andres Felipe Cardona
    Wagman, Joanne
    Chen, Xinqun
    Zhao, Bin
    Schulz, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC)
    Elamin, Yasir
    Gomez, Daniel Richard
    Papadimitrakopoulou, Vassiliki
    Tran, Hai T.
    Rinsurongkawong, Waree
    Lewis, Jeff
    Lacerda, Lara
    Roarty, Emily
    Lee, J. Jack
    Roth, Jack A.
    Swisher, Stephen
    Zhang, Jianjun
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345